Erasca (ERAS) Operating Income (2020 - 2026)
Erasca posted quarterly Operating Income of -$187.9 million for Q1 2026, down 427.4% year-on-year from $57.4 million in Q1 2025, and down 476.34% on a QoQ basis from -$32.6 million in Q4 2025.
Erasca (ERAS) has 7 years of Operating Income data on file, last reported at -$187.9 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 427.4% year-over-year to -$187.9 million; the trailing twelve-month figure through Mar 2026 stood at -$293.2 million (down 66.24% YoY), and the FY2025 full-year result was -$140.9 million, up 21.54% from the prior year.
- Operating Income for Q1 2026 stood at -$187.9 million, down from -$32.6 million in the prior quarter.
- Across five years, Operating Income topped out at -$32.6 million in Q4 2025 and bottomed at -$187.9 million in Q1 2026.
- The 5-year median for Operating Income is -$36.5 million (2022), against an average of -$52.8 million.
- The widest annual swing landed in 2023, when Operating Income jumped 75.47%; it then slumped 427.4% in 2026.
- A 5-year view of Operating Income shows it stood at -$138.1 million in 2022, then surged by 75.47% to -$33.9 million in 2023, then retreated by 5.43% to -$35.7 million in 2024, then rose by 8.7% to -$32.6 million in 2025, then tumbled by 476.34% to -$187.9 million in 2026.
- The last three Operating Income figures came in at -$187.9 million (Q1 2026), -$32.6 million (Q4 2025), and -$34.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -187.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -187.91 Mn |
| Dec 31, 2025 | -32.60 Mn |
| Sep 30, 2025 | -34.55 Mn |
| Jun 30, 2025 | -38.13 Mn |
| Mar 31, 2025 | -35.63 Mn |
| Dec 31, 2024 | -35.71 Mn |
| Sep 30, 2024 | -37.24 Mn |
| Jun 30, 2024 | -67.78 Mn |
| Mar 31, 2024 | -38.85 Mn |
| Dec 31, 2023 | -33.87 Mn |
| Sep 30, 2023 | -34.66 Mn |
| Jun 30, 2023 | -35.97 Mn |
| Mar 31, 2023 | -37.03 Mn |
| Dec 31, 2022 | -138.08 Mn |
| Sep 30, 2022 | -36.96 Mn |
| Jun 30, 2022 | -35.91 Mn |
| Mar 31, 2022 | -36.51 Mn |
| Dec 31, 2021 | -31.05 Mn |
| Sep 30, 2021 | -46.04 Mn |
| Jun 30, 2021 | -28.18 Mn |
| Mar 31, 2021 | -19.61 Mn |
| Dec 31, 2020 | -66.97 Mn |
| Sep 30, 2020 | -11.16 Mn |
| Jun 30, 2020 | -7.28 Mn |